Research Projects & Grants

For Profit Organization

  • A Multicenter, Prospective, Open label, Randomized Controlled Clinical Trial to Compare the Safety and Effectiveness of the VitaSmart™ Liver Machine Perfusion System with Static Cold Storage for Organ Preservation Prior to Liver Transplantation BTL-2020-01 vs - Version 4.0 dated Sept. 23, 2021, Role: PI, Bridge to Life, Ltd, (12/2023 - 08/2024) Status: Completed
  • A phase 3 prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transplants, Role: PI, Medeor Therapeutics, Inc., (05/2023 - 04/2024) Status: Completed
  • Post-marketing requirement study to evaluate the safety of Octaplas™ versus plasma in patients undergoing orthotopic liver transplantation with special emphasis on hyperfibrinolysis, Role: PI, Octapharma, (06/2018 - 06/2019) Status: Completed
  • A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015), Role: PI, Novartis Pharmaceuticals Corporation, (02/2018 - 02/2019) Status: Completed
  • A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015), Role: Investigator, Oxford Immunotec, (07/2017 - 07/2018) Status: Completed
  • A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure (Eisai, May 2015), Role: Investigator, Eisai Medical Research, Inc., (08/2016 - 08/2017) Status: Completed
  • A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant grifols (FS Grifols) as an adjunct to hemostasis during parenchymous tissue open surgeries (Protocol IG1102 version 2.1: 24 October 2012), Role: PI, Instituto Grifols, S.A., (03/2016 - 03/2017) Status: Completed
  • A multicenter, double-blind, placebo controlled study to evaluate the safety, tolerability and efficacy of IDN-6556 in subjects with liver cirrhosis (conatus cirrhosis 9Jun14), Role: Investigator, Conatus Pharmaceuticals Inc., (07/2015 - 07/2016) Status: Completed
  • A multicenter, randomized, open-label, active-controlled, trial to evaluate the safety and efficacy of rifaximin 550 mg with and without lactulose in subjects with a history of recurrent overt hepatic encephalopathy (RFHE, 4044-12Oct12), Role: Investigator, Salix Pharmaceuticals, Inc., (04/2014 - 04/2015) Status: Completed
  • Non-interventional, prospective, cohort study of the effectiveness, safety, and utilization of two approved pegylated interferon-based direct acting antiviral triple therapies in the management of Genotype 1 chronic Hepatitis C in routine clinical practice in the USA, Role: PI, Genentech, Inc., (03/2014 - 03/2015) Status: Completed
  • A phase 3, double-blind, double-dummy, multi-center, prospective, randomized study of the efficacy and safety of LCP-Tacro™ tablets, once daily, compared to Prograf® capsules, twice daily, in combination with mycophenolate mofetil for the prevention of acute allograft rejection in De Novo adult kidney transplant recipients (protocol LCP-Tacro 3002 version 3.0 September 30, 2010), Role: Investigator, LifeCycle Pharma A/S, (10/2013 - 10/2014) Status: Completed

Internal

  • The role of B cells in kidney allograft dysfunction (B cell 3/1/2014), Role: PI, LLU Transplantation Institute, (06/2022 - 06/2023) Status: Completed
  • Pilot investigation using HCV positive liver grafts in HCV negative or previously successfully treated recipients, Role: Investigator, LLU Dept. of Medicine, (02/2022 - 02/2023) Status: Completed
  • Hematologic and Immune Cell Ratios in the Prediction of Outcomes After Solid Abdominal Organ Transplantation, Role: Investigator, LLU Dept. of Surgery, (07/2021) Status: Approved
  • Highly Suppressive Regulatory T Cell as a Biomarker for Immunologically Relevant Delayed/Slow Graft Function after Kidney Transplantation, Role: Investigator, LLU Dept. of Surgery, (10/2020) Status: Approved
  • Randomized controlled trial of transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma, Role: PI, LLU Dept. of Surgery, (07/2020 - 07/2021) Status: Completed
  • Hepatocellular carcinoma (HCC) outcomes after liver transplantation (LT), Role: PI, LLU Dept. of Surgery, (03/2020) Status: Approved
  • The role of B cells in systemic lupus erythematosus patients, Role: Investigator, LLU Transplantation Institute, (09/2018 - 09/2019) Status: Completed
  • The Role of B Cells in Kidney Allograft Dysfunction, Role: PD/PI, LLU School of Medicine, (01/2014 - 06/2016) Status: Closed
  • Clinical outcomes of induction therapies in renal transplant patients, Role: Investigator, LLU Transplantation Institute, (12/2007 - 12/2015) Status: Completed

Non-Profit Organization

  • Integration of donor-derived cell-free DNA with HLA-DR+TNFR2+ regulatory T cell in the prediction of acute rejection and graft function after kidney transplantation, Role: Investigator, American Society of Transplant Surgeons, (08/2024 - 08/2025) Status: Approved